MEDICINOVA INC (MNOV) research
MEDICINOVA INC- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.78
- As of
MEDICINOVA INC (MNOV): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-28.
As of . Source: SEC EDGAR filings for MNOV. Method and limitations.
Share the MNOV intelligence card
See the full MNOV dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for MNOV on one page. Preview it with sample data, then open it live with a free account.
Preview the MNOV dossierActive signals for MNOV
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 22.6%, EPS $-0.05 vs $-0.0646 estimate
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 55% of MNOV (2026Q2)
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 27.8% - EPS $-0.07 vs $-0.0969 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 41.2% - EPS $-0.06 vs $-0.102 estimate
- mediumEARNINGS_BEAT
Q4-2025: Beat consensus by 27.8% - EPS $-0.07 vs $-0.0969 estimate
FREE, NO ACCOUNT
Every signal on MNOV, as it fires
You are seeing 5 of 8 signals recorded on MNOV since 2026-05-24.
The five above landed across 4 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in MNOV (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 58468P206 · 2026Q2 | $271K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 58468P206 · 2026Q2 | $18K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, MNOV
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
MNOV against its peers
MNOV's operating margin of -3242.5% ranks in the 23rd percentile of 10 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-01-31.
| Metric | MNOV | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 409657 USD | 3.6M USD | 27 | 12 |
| Operating margin | -3242.5% | -346.1% | 23 | 10 |
| Net margin | -2928.8% | -404.1% | 38 | 11 |
| Return on equity | -28.9% | -123.2% | 88 | 19 |
Peers (22): KZIA, MIST, EQ, NTRB, VXRT, PYPD, PLYX, BDTX, IMUX, ANIX, OKUR, GNLX, PMN, NMRA, CBUS, LENZ, VANI, CRDF, BMEA, NRXS, AARD, COYA. Left out: CNXU (no annual filing), HSTC (period gap), SPRC (period gap). Fiscal periods ending between 2025-06-30 and 2026-01-31. Every figure is one full fiscal year read from one annual filing (MNOV: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more MNOV signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to MNOVand get the insider, 13F, options, and confluence read in one view.